Table 2.
Study measurements for septic and control patients
| Laboratorya | n | Septicb Median (IQR) |
n | Febrile Controls Median (IQR) |
n | Healthy Controls Median (IQR) |
pc |
|---|---|---|---|---|---|---|---|
| ADMA, day 1 | 26 | 0.38 (0.30–0.56) | 30 | 0.45 (0.40–0.59) | 30 | 0.60 (0.54–0.67) | <0.001d |
| ADMA, day 2 | 25 | 0.43 (0.35–0.54) | <0.001 | ||||
| Arginine, day 1 | 12 | 10 (7–20) | 30 | 13 (8–26) | 30 | 32 (23–40) | <0.001 |
| Arginine, day 2 | 24 | 10 (7–27) | <0.001 | ||||
| Citrulline, day 1 | 12 | 8 (4–10) | 30 | 9 (6–12) | 30 | 16 (13–19) | <0.001 |
| Citrulline, day 2 | 24 | 8 (4–17) | <0.001 | ||||
| Ornithine, day 1 | 12 | 30 (16–59) | 30 | 23 (19–72) | 30 | 45 (35–60) | 0.012 |
| Ornithine, day 2 | 24 | 43 (19–81) | 0.05 | ||||
| Arg:ADMA, day 1 | 12 | 33.2 (15.1–65.7) | 30 | 26.7 (17.8–63.4) | 30 | 54.3 (44.7–67.3) | 0.051 |
| Arg:ADMA, day 2 | 23 | 24.7 (16.9–67.7) | 0.06 | ||||
| Citr:Arg, day 1 | 12 | 0.52 (0.46–1.05) | 30 | 0.59 (0.39–0.76) | 30 | 0.52 (0.42–0.70) | 0.82 |
| Citr:Arg, day 2 | 24 | 0.58 (0.40–1.10) | 0.84 | ||||
| Arg:Orn, day 1 | 12 | 0.44 (0.24–0.56) | 30 | 0.53 (0.37–0.68) | 30 | 0.63 (0.52 (0.79) | 0.03 |
| Arg:Orn, day 2 | 24 | 0.35 (0.25–0.52) | 0.002 | ||||
| AC:FC, day 1 | 12 | 1.25 (0.44–1.98) | 30 | 0.78 (0.72–1.27) | 30 | 0.93 (0.77–1.17) | 0.67 |
| AC:FC, day 2 | 24 | 1.33 (0.60–2.03) | 0.46 | ||||
ADMA, asymmetric dimethylarginine; Arg:ADMA, arginine:asymmetric dimethylarginine ratio; Citr:Arg, citrulline:arginine ratio; Arg:Orn, arginine:ornithine ratio; AC:FC, acylcarnitine:free carnitine ratio
a
Units are µmol/L
b
Since not all measurements were available on every study day for septic patients, day 1 and 2 values are reported for comparison
c
Comparisons made using Kruskal-Wallis test for day 1 and day 2 values for septic patients versus control groups
d
ADMA (day 1) between septic and febrile patients, only, p=0.056; ADMA between septic and healthy patients, only, p<0.001; ADMA between febrile and healthy patients, only, p=0.003